<?xml version="1.0" encoding="UTF-8"?>
<p>More recently, the US Food and Drug Administration released a Guidance to Industry paper entitled “Drug Products including biological products that contain nanomaterials” [(
 <xref rid="B20" ref-type="bibr">20</xref>) see also for Liposomes final guidance under (
 <xref rid="B21" ref-type="bibr">21</xref>)], where a number of concepts and recommendations are given for the development of innovative or follow-on/ similar products falling into the NBCD category. The guidance proposes a so called 
 <italic>risk-based approach</italic>, presuming that potential risks can be anticipated based on: (i) Adequate characterization of the nanomaterial; (ii) Understanding of a nanomaterial's intended use; and (iii) Application, and how the nanomaterial attributes relate to product quality, safety, and efficacy.
</p>
